stocksfever.com Open in urlscan Pro
46.4.98.170  Public Scan

Form analysis
3 forms found in the DOM

GET https://stocksfever.com

<form role="search" method="get" class="responsive-search-form" action="https://stocksfever.com">
  <label>
    <input type="search" class="responsive-search-field" placeholder="Search …" value="" name="s">
  </label>
  <span class="dashicons dashicons-search responsive-search-icon"></span>
</form>

GET https://stocksfever.com

<form role="search" method="get" class="search-form" action="https://stocksfever.com"><input type="search" class="search-field" placeholder="Search …" value="" name="s"><input type="submit" class="search-submit" value=""></form>

GET https://stocksfever.com

<form role="search" method="get" class="search-form" action="https://stocksfever.com"><input type="search" class="search-field" placeholder="Search …" value="" name="s"><input type="submit" class="search-submit" value=""></form>

Text Content

TSCO.L 287.90 -0.45 -0.16% AAPL 176.28 0.64 0.36% MSFT 334.69 1.49 0.45% TSLA
1,067.00 58.13 5.76% GOOG 2,942.85 3.87 0.13% EBAY 64.89 0.95 1.49% FB 335.24
4.79 1.45% TWTR 44.16 0.26 0.59% CS 9.69 0.16 1.68% JPM 157.26 0.56 0.36% GE
94.00 0.93 1.00% DB 12.62 0.17 1.37% NFLX 614.09 -0.15 -0.02% MU 94.42 4.08
4.52% AMZN 3,421.37 0.63 0.02% ORCL 89.72 -0.14 -0.16% JPM 157.26 0.56 0.36% DIS
153.63 1.75 1.15% BAC 44.42 0.14 0.32% BABA 118.66 0.85 0.72% BNS 69.79 0.69
1.00% KO 58.22 0.04 0.07% NKE 165.67 0.23 0.14%
TSCO.L 287.90 -0.45 -0.16% AAPL 176.28 0.64 0.36% MSFT 334.69 1.49 0.45% TSLA
1,067.00 58.13 5.76% GOOG 2,942.85 3.87 0.13% EBAY 64.89 0.95 1.49% FB 335.24
4.79 1.45% TWTR 44.16 0.26 0.59% CS 9.69 0.16 1.68% JPM 157.26 0.56 0.36% GE
94.00 0.93 1.00% DB 12.62 0.17 1.37% NFLX 614.09 -0.15 -0.02% MU 94.42 4.08
4.52% AMZN 3,421.37 0.63 0.02% ORCL 89.72 -0.14 -0.16% JPM 157.26 0.56 0.36% DIS
153.63 1.75 1.15% BAC 44.42 0.14 0.32% BABA 118.66 0.85 0.72% BNS 69.79 0.69
1.00% KO 58.22 0.04 0.07% NKE 165.67 0.23 0.14%
Stocks Fever

 * Home
 * 
 * Investing News
 * Market Insider
 * Stock Market
 * Stocks to buy
 * Stocks to sell
 * Dividend Stocks
 * Trader Talk
 * Videos
 * Contact
   * About us
   * Amazon Disclaimer
   * DMCA / Copyrights Disclaimer
   * Privacy Policy
   * Terms and Conditions
 * 

Skip to content
Stocks Fever
Latest stock market news and investing guides.
 * 
 * Investing News
 * Market Insider
 * Stock Market
 * Stocks to buy
 * Stocks to sell
 * Dividend Stocks
 * Trader Talk
 * Videos
 * Contact
   * About us
   * Amazon Disclaimer
   * DMCA / Copyrights Disclaimer
   * Privacy Policy
   * Terms and Conditions
 * 



Under the Radar Company Levitee Labs, Inc. (OTC: LVTTF) Could Soon Become the
Next Big Winner in the Psychedelic Revolution!



Meet the Small-Cap Company Redefining Traditional Mental Health Treatments to
Empower ALL People to Heal and Elevate Their Well Being!

As the Conversation About Psychedelics Heats Up, Levitee Labs, Inc. (OTC: LVTTF)
(CSE: LVT) May Be Poised for Explosive Upside Ahead!



https://leviteelabs.com/

At the forefront of revolutionary addiction and mental health treatment is
Levitee Labs, Inc. (OTC: LVTTF), an exciting up and coming company that could
quickly see astronomical movement as it gains attention for its psychedelic
therapies and complementary medicines.

THIS QUIETLY TRADING Small Cap Company is IN A UNIQUE POSITION TO CHALLENGE THE
NARRATIVE WHEN IT COMES TO TREATING MENtAL HEALTH AND ADDICTION ALL WHILE
POTENTIALLY CREATING SUBSTANTIAL SHAREHOLDER GROWTH!



Levitee Labs, Inc. (OTC: LVTTF) (CSE: LVT) is establishing itself as a leader in
the integrative wellness space – an arena that combines what works best with
conventional medicine and applies it to alternative based practices.

Through leveraging an M&A regimen that focuses on the centralization of
complementary integrative wellness assets, (OTC: LVTTF) (CSE: LVT) aims to
transform mental health and addiction treatments through the integration of
psychedelic medicines and therapies.

Company Video:

https://vimeo.com/635612717?embedded=true&source=vimeo_logo&owner=154836226

THE TOP 10 REASONS TO HAVE Levitee Labs, Inc. ON YOUR WATCHLIST RIGHT NOW:

 1.  A profitable portfolio of complementary integrative wellness assets – the
     company has acquired 5 mental health and addiction clinics, 3 specialized
     pharmacies, a proprietary addiction-focused technology platform, an
     omnichannel nutraceuticals company, and built a mushroom feedstock
     manufacturing facility.
 2.  Comparable mental health companies are trading significantly higher
     including Acadia Healthcare (NASDAQ: ACHC) at over $50 a share and LHC
     Group (NASDAQ: LHC) at over $100 a share!
 3.  Strong acquisition pipeline includes over $500M in revenue and $100M in
     EBITDA (pre-synergies)!
 4.  Established portfolio of cash flowing assets through accretive M&A – 2021E
     year-end expected run-rate revenue of $22.8M!
 5.  Key partnerships in place, including a master distribution agreement and
     strategic alliance with My Green Planet, an Agreement with Adracare, a WELL
     Health Technologies company. The major distribution partnership with My
     Green Planet highlights $6.0M 2021E year-end run-rate revenue!
 6.  The Earth Circle Organics acquisition highlights a 300% growth over 2 years
     and $3M LTM revenue, $750k LTM EBITDA!
 7.  Company is headed by professionals with extensive experience in healthcare
     and finance, amongst other diversified industries!
 8.  The company is active in identifying additional acquisition targets of
     operating businesses that provide synergistic value!
 9.  According to Canaccord Genuity Capital Markets, the addressable psychedelic
     medicine market is a staggering $100B!
 10. The mental health, addiction and chronic pain space is ripe for
     transformative innovation and the company is positioned at the forefront of
     it — blending traditional health systems with the new frontier of
     value-based health solutions, including psychedelic medicines and
     digitization, for better patient outcomes.

Keep on reading to find out how Levitee Labs, Inc. is becoming an exciting
game-changer for treating mental health and addiction, and why share prices
could be ready to skyrocket!

Greetings Investors,

The growing economical, psychological, and clinical burden of mental health,
addiction, and chronic pain needs to be addressed. There is a major gap between
what the system currently provides and what patients need.

Levitee Labs, Inc. (OTC: LVTTF) (CSE: LVT) is focused on providing a solution to
this huge problem!

The Mental Health, Substance Use, and Chronic Pain crises have NOT been
addressed properly.

 * According to the CDC, over 50% of Americans will be diagnosed with a mental
   or substance use disorder in their lifetime.
 * A dire statistic is that 1 out of 10 Americans are currently suffering from
   some kind of substance abuse. Only 11% of these people who seek treatment are
   getting the care they need.
 * Medscape has also found that drug overdoses have become the number one cause
   of injury-related death in the U.S., killing 44,000 people annually.
 * The CDC has also found that chronic pain affects approximately 50 million
   U.S. adults.
 * The Canadian Federal Budget Report as of April 20th, 2021, found that Canada
   suffered a 74% increase in opioid-related deaths over the course of the first
   six months of the pandemic.
 * Access to services is a major barrier, with the sector receiving only 7% of
   health care dollars and wait times for care are greater than one year for
   many publicly funded pain clinics.

Psychedelics have shown therapeutic benefit in disorders such as depression,
addiction, and PTSD. These are internalizing disorders, in which negative
thoughts are reiterated over and over again and often get no relief and can be
treatment-resistant.

The exciting results of early psychedelic research have been promising. A 2016
meta-analysis of 19 studies that used psychedelics to treat mood disorders
between 1949 and 1973 found that 79% of participants showed “clinically judged
improvement.”

80% of patients describe their psychedelic experience as one of the “most
personally meaningful and spiritually significant experiences of their life” as
the experience gets to the root of their symptoms!

We live in an exciting time where we can push past outdated stigmas on the “war
on drugs” and can explore the untapped potential for mental health and addiction
rehabilitation thanks in part to Levitee Labs, Inc. (OTC: LVTTF) (CSE: LVT)!

The company is bursting the bubble of what is considered “the norm” and is now
one of the most exciting health care companies to take notice of!



Incorporated in 2019, Levitee Labs, Inc. (OTC: LVTTF) (CSE: LVT) believes in
leading change in the integrative wellness landscape from the inside out.

The company is redefining the global approach to preventing, healing, and
transforming mental health, addiction, and chronic pain disorders because the
current approach leaves too many people suffering.

Levitee Labs is bridging traditional mental health, addiction, and pain
management treatments with psychedelic applications by building a path that
previously didn’t exist through its integrative wellness platform.

This platform will transform the system that poses barriers to the wellbeing of
people living with mental health, addiction, and chronic pain!

The company’s integrative wellness platform empowers the human will to improve
and get better, starting from any baseline. People need improved access to and
quality of value-based patient care to heal and elevate.

Levitee Labs specializes in developing and acquiring cash flowing integrative
wellness assets and provides a wide range of curative wellness tools from these
assets so everyone can experience not only mental and physical optimization, but
also a reduction in symptoms related to a lack of integrative wellbeing.

The Company’s current portfolio of assets includes:

 * Levitee Clinics™, a group of five operating addiction and pain treatment
   clinics in Alberta. The clinics treat over 20,000 addiction and pain
   management patients annually. (ACT Medical Centres | Chronic Pain & Addiction
   Treatment)
 * Levitee Pharmacies™, three pharmacies operating in Alberta specialized in
   filling prescriptions for patients with substance use disorders, mental
   health conditions, and chronic pain;
 * BlockMD, the first technology company in Alberta to receive provincial
   approval for electronic-prescriptions in the addiction treatment space;
 * Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and
   superfood products with 180+ SKUs in its product lineup across three brands.

Levitee Clinics and Pharmacies





STRATEGY





WELL HEALTH TECNOLOGIES AGREEMENT



◇ Levitee Labs has entered into an agreement with Adracare, a portfolio company
of Well Health Technologies (TSX: WELL)

◇ Adracare is a leading provider in virtual care telemedicine; WELL is an
innovative healthcare company which integrates technology into its service
offerings

◇ WELL is now able to provide Levitee Labs with full access to their
comprehensive end-to-end practice management solutions

◇ This partnership enables Levitee Labs to enhance the quality and accessibility
of health and wellness services offered to patients, including psychedelics and
telemedicine

[We’re] “rolling-up addiction focused businesses and services under the Levitee
Clinics and Pharmacies brand, digitizing these assets and creating a medical
home model of care, through WELL Health Technologies’ state-of-the art
comprehensive digital platforms, to be able to deliver care to individuals most
in need, in a scalable and efficient manner.”

– Dr. Fady Hannah-Shmouni, Chief Medical & Scientific Officer, President of
Clinics

Levitee Nutraceuticals





ADDITIONAL ACQUISITION TARGETS



Substance Abuse & Harm Statistics



Financial Snapshot





Recent Developments

 * Signed LOI to acquire 100% interest in chain of specialty addiction
   pharmacies in Vancouver, BC
 * Acquisition price of $4.0 million based upon approximately 4.7x trailing 6
   months annualized EBITDA of $850,000
 * The chain operates 3 locations, which will be added to the Levitee Pharmacies
   growing portfolio of locations throughout Alberta and British Columbia

“This acquisition is our first move into our home province of British Columbia,
a province where the opioid epidemic and addiction has been a major visible
problem for decades.”

– Ken Osborne, Head of Mergers & Acquisitions at Levitee Labs

“We have grown tremendously since closing multiple acquisitions in July that
positioned us with a formidable footprint of clinics and pharmacies in Alberta.
This is our second largest acquisition to date and provides us a solid
foundation to build upon in British Columbia, as we establish the Levitee Labs
name as a dominant player in treating patients suffering from addiction and
substance use disorder throughout Western Canada.”

– Pouya Farmand, Chief Executive Officer at Levitee Labs

– Levitee Labs is also acquiring 51% interest in new R&D compounding pharmacy in
Calgary, Alberta, Canada

– New pharmacy to focus on production of intranasal ketamine and sublingual
preparations, topical and transdermal formulations, capsules and other
Levitee-branded compounds and products

The acquisition represents the launch of the Company’s initiative into
production and distribution of pharmaceutical products under the Levitee Labs
banner!

The Bottom Line:

The Next Generation of Treating Mental Health and Addiction is Here and (OTC:
LVTTF) (CSE: LVT) is an Emerging Company That Could Lead the Way!



Addiction is an unforgiving disorder that destroys countless lives and tears
apart families in nearly every corner of the globe. Mental health has also
become one of the most top priorities among patients when they consider
healthcare!

Depression can raise the risk for many types of physical health problems,
particularly long-lasting conditions like diabetes, heart disease, and stroke.

Levitee Labs, Inc. (OTC: LVTTF) (CSE: LVT) has seen consistent growth across all
its divisions, with accumulated revenue from September to October broken down
into the following subdivisions: 28.1% for Levitee Clinics, 40.7% for Levitee
Pharmacies, and 31.1% for Earth Circle Organics and other wellness products!

The company is also now the LARGEST non-governmental provider of addiction care
in the Province of Alberta, servicing over 35,000 patients annually!

As media awareness for new psychedelic treatments of mental health disorders and
treating addiction continues to grow, and more studies show the value that it
may have in treating mental disorders, LVTTF could become a tremendous
healthcare growth story!

Also keep in mind that (OTC: LVTTF) (CSE: LVT) is undervalued on an Enterprise
Value basis compared to its peers, demonstrating tremendous upside potential at
current levels!



Hurry and start your research, today while the company is still heavily trading
under the radar!


PRODUCTS YOU MAY LIKE

Fire 7 Tablet | 7" display, 16 GB, Black - with Ads
£29.99
£49.99

(69,980)
Fire HD 10 tablet | 10.1", 1080p Full HD, 32 GB, Black - without Ads
£99.99
£159.99

(5,658)
Fire HD 8 Tablet, 8" HD display, 32 GB, Black - with Ads, designed for portable
entertainment
£69.99
£89.99

(23,792)
Galaxy Tab A7 Lite 32GB Grey WIFI
£119.00
£149.00

(445)
Fire 7 Kids tablet | for ages 3-7 | 7" Display, 16 GB | Blue Kid-Proof Case
£59.99
£99.99

(29,274)
Lenovo Tab M10 10.1 Inch HD Tablet – (Quad Core 2.0GHz, 2GB RAM, 32GB eMMC,
Android Pie) – Slate Black
£129.99
£139.99

(678)
Samsung Galaxy Tab A7 32 GB Wi-Fi Android Tablet - Dark Grey (UK Version)
£179.00
£219.00

(5,090)
Tablet 10 Inch 8 Core - TOSCIDO Android 10.0 Certified by Google GMS 4G LTE
Tablets, 4GB of RAM and 64 GB, Dual SIM, GPS, WiFi, Bluetooth
Keyboard,Mouse,Tablet Case and More Included (Gray)
£119.95

(2,477)
Ads by Amazon


STOCK PRICES

Symbol Last Price Change % Change AAPL 176.28 0.64 0.36% MSFT 334.69 1.49 0.45%
TSLA 1,067.00 58.13 5.76% GOOG 2,942.85 3.87 0.13% EBAY 64.89 0.95 1.49% NFLX
614.09 -0.15 -0.02% MU 94.42 4.08 4.52% FB 335.24 4.79 1.45% AMZN 3,421.37 0.63
0.02% ORCL 89.72 -0.14 -0.16% JPM 157.26 0.56 0.36% TWTR 44.16 0.26 0.59% DIS
153.63 1.75 1.15% BAC 44.42 0.14 0.32% BABA 118.66 0.85 0.72%

Follow us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Follow us on Pinterest
Follow us on Instagram
Follow us on YouTube



INVESTING NEWS

 * How to Convert a 401(k) to a Roth 401(k)
 * Top Strategies for Perfecting Pullback Trading
 * What the top crypto execs predict for the industry in 2022: Regulation and a
   Big Tech ‘brain drain’
 * Nikola shares surge 18% after company delivers its first EV truck, says more
   to come
 * How to Grow an IRA to $100 Million Plus
 * Meme stocks, SPAC craze and a $100 million deli: It was a wild year in the
   market
 * When Not to Open a Roth IRA
 * Options trading activity hits record powered by retail investors, but most
   are playing a losing game
 * Best Small-Cap ETFs for Q1 2022
 * Cramer still believes in Santa Claus rally into end of 2021 even as Covid
   omicron cases spike

The Financial Times Guide to Investing: The Definitive Companion to Investment
and the Financial Markets (The FT Guides)
£19.99
£27.99

(287)
The Economist Guide To Investment Strategy 4th Edition: How to understand
markets, risk, rewards and behaviour
£11.85
£15.00

(28)
The Investment Trust Handbook 2021: Investing essentials, expert insights and
powerful trends and data
£16.92
£29.99

(106)
The Motley Fool Investment Guide: How the Fools Beat Wall Street's Wise Men and
How You Can Too
£15.10
£16.58
(353)
Ads by Amazon


STOCK MARKET

 * BlackBerry is a Tough Buy That Will Test Investor Patience
 * DigitalOcean: Learnings From a Record Year for the IPO Market
 * Robinhood’s Risk-to-Reward Ratio Is Improving
 * Why It’s Not the Time to Buy the Dip on Upstart
 * Virgin Galactic Is Lagging in the Commercial Space Race, and It’s a Problem

Money: A User’s Guide: The Sunday Times bestselling guide to taking control of
your personal finances
£6.55
£7.99

(1,392)
The Infographic Guide to Personal Finance: A Visual Reference for Everything You
Need to Know
£10.72
£12.67

(626)
Personal Finance For Dummies
£12.85
£17.99

(681)
PERSONAL FINANCE FOR COLLEGE STUDENTS, TEENS AND YOUNG ADULTS & RETIREMENT
PLANNING FOR 50+ : A 28-DAYS GUIDE TO LEARNING MONEY MANAGEMENT SKILLS TO SAVE,
PAY OFF DEBT, INVEST AND RETIRE EARLY
£0.77
Ads by Amazon


STOCKS TO BUY

 * Why Nike Stock Keeps Proving the Skeptics Wrong
 * Ford Has Successfully Reinvented Itself As An Electric Vehicle Maker
 * Rivian Stock Looks Poised to Rebound
 * Why Twilio Stock Is Still Slumping
 * 7 Beaten-Down Growth Stocks to Buy for 2022


CATEGORIES

 * Dividend Stocks
 * Investing News
 * Market Insider
 * Stock Market
 * Stocks to buy
 * Stocks to sell
 * Trader Talk
 * Videos


ARCHIVES

 * December 2021
 * November 2021
 * October 2021
 * September 2021
 * August 2021


CATEGORIES

 * Dividend Stocks
 * Investing News
 * Market Insider
 * Stock Market
 * Stocks to buy
 * Stocks to sell
 * Trader Talk
 * Videos


USEFUL LINKS

 * Contact us
 * About us
 * Amazon Disclaimer
 * DMCA / Copyrights Disclaimer
 * Privacy Policy
 * Terms and Conditions


RECENT ARTICLES

 * BlackBerry is a Tough Buy That Will Test Investor Patience
 * Why Nike Stock Keeps Proving the Skeptics Wrong
 * ChargePoint Stock Is Not a Good Bet at This Time
 * How to Convert a 401(k) to a Roth 401(k)
 * DigitalOcean: Learnings From a Record Year for the IPO Market

Copyright © 2021 by Stocks Fever. All rights reserved. All articles, images,
product names, logos, and brands are property of their respective owners. All
company, product and service names used in this website are for identification
purposes only. Use of these names, logos, and brands does not imply endorsement
unless specified. By using this site, you agree to the Terms of Use and Privacy
Policy.

Powered by WordPress using DisruptPress Theme.